Modern Most Neglected Stocks : RNIN, MM, FRO, AFFY

New York, NY -- (SBWIRE) -- 03/06/2013 -- Wireless Ronin Te (NASDAQ:RNIN) is very active today and traded between $1.98 - 2.33 with total traded volume of 765281 shares. At a current price of 1.98, RNIN is -0.75 - -27.47% from the previous close of $2.73. Moreover, At Current Market Price, RNIN is in distance of -2.84% from its 50-day Moving Average price of $2.0379 and -35.77% from its 200-day Moving Average price of $3.0825.

How Should Investors React To RNIN Now? Find Out Here

Investment analysts at Needham & Company assumed coverage on shares of Millennial Media (NYSE:MM) in a note issued to investors on Tuesday. The firm set a “hold” rating on the stock.

Millennial Media opened at 8.96 on Tuesday. Millennial Media has a 1-year low of $8.78 and a 1-year high of $27.90. The stock’s 50-day moving average is currently $11.28. The company’s market cap is $710.2 million.

Millennial Media last posted its quarterly earnings results on Tuesday, February 19th. The company reported $0.03 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.03. The company had revenue of $58.00 million for the quarter, compared to the consensus estimate of $62.89 million. Millennial Media’s revenue was up 68.1% compared to the same quarter last year. Analysts expect that Millennial Media will post $0.14 EPS for the current fiscal year.

Should A Trader Buy Or Sell MM Now : CHECK HERE

Frontline Ltd. (NYSE:FRO) is a shipping company. The Company is engaged primarily in the ownership and operation of oil tankers and oil/bulk/ore (OBO) carriers. Shares of Frontline Ltd. Or (NYSE: FRO) are trading at $1.85 and is -39.39% of its 50-day Moving Average price of $3.0524 and -45.59% from its 200-day Moving Average price of $3.4001. The average trading volume is 785698 shares and its market capitalization is $144.0M.

Should Investors Buy FRO Now? Free Sign Up Here For FRO Analyst Report

Affymax, Inc. (NASDAQ:AFFY) is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, peginesatide, is for the treatment of anemia in chronic kidney disease patients on dialysis. Peginesatide is a synthetic peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells.

The share of Affymax, Inc. (NASDAQ: AFFY) reported EPS of -1.523. For the Current Fiscal year, the company is expected to report EPS of -1.31. For the Next Quarter and Next Year, the company is expected to report EPS of -0.55 and -1.79 respectively. At Current Market Price, AFFY is in distance of -84.41% from its 50-day Moving Average price of $15.1374 and -88.24% from its 200-day Moving Average price of $20.0737.

Should Investor Buy OR Sell This Stock: CLICK HERE

DISCLAIMER:

Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.biz